Search Results

You are looking at 21 - 30 of 282 items for :

  • All content x
Clear All
Restricted access

Katrine Dahl Bjørnholm, Gro Klitgaard Povlsen, Maria Elm Ougaard, Charles Pyke, Günaj Rakipovski, Pernille Tveden-Nyborg, Jens Lykksefeldt, and Gry Freja Skovsted

The glucagon-like peptide-1 receptor (GLP-1R) is expressed in the renal vasculature and known to be decreased under hypertensive conditions in rats and humans. However, little is known about the regulation in other types of renal pathology involving vascular changes. This study investigates the expression of the GLP-1R in renal vasculature after glomerular injury in the nephrotoxic nephritis mouse model, high cholesterol, and atherosclerosis in the Ldlr-/- mouse on western diet, and ex vivo injury in an organ culture model. The immunohistochemical signal of the GLP-1R was significantly decreased in arteries from mice with nephrotoxic nephritis after 42 days compared to 7 days and saline control (p<0.05). Histological evaluation of kidneys from Ldlr-/- mice on western diet showed a decreased GLP-1R specific immunohistochemical signal (p<0.05). The dilatory response to liraglutide was decreased in western diet fed Ldlr-/- mice compared to C57Bl/6J controls (p<0.05). Organ culture significantly decreased the immunohistochemical signal of the GLP-1R (p<0.05) and the expression of Glp-1r mRNA (p<0.005) compared to fresh. Organ cultured vessels showed vascular smooth muscle cell remodelling as Acta2 expression was decreased (p<0.005) and Ednrb was increased (p<0.05).

In conclusion, nephrotoxic nephritis and hypercholesterolemia led to decreased GLP-1R specific immunohistochemical signal. Ex vivo vascular injury in the organ culture model lead to a decrease in expression of GLP-R expression and contractile VSMC specific markers and increase in expression of dedifferentiation markers suggestive of an inverse relationship between phenotypic swich of the VSMC and the expression of the GLP-1R however, the causal relationship remains elusive.

Open access

Alyce M Martin, Emily W Sun, and Damien J Keating

-like peptide 1 (GLP-1), peptide YY (PYY) and oxyntomodulin (OXM), and glucose-dependent insulinotropic peptide (GIP) secreting K cells. It is now clear that such a classification system is not accurate given the accumulation of evidence that cross-over in

Free access

Sara Baldassano, Anna Lisa Bellanca, Rosa Serio, and Flavia Mulè

were in compliance with the guidelines of the European Communities Council Directive of 24 November 1986. Diets After 1 week of free access to a pelletized rodent diet (GLP4RF21; Mucedola, S.r.L. Italy), mice were divided into two groups. One group were

Free access

K K Sidhu, R C Fowkes, R H Skelly, and J M Burrin

Introduction Glucagon-like peptide 1 (GLP-1) is a proglucagon-derived peptide hormone that is synthesized and secreted by intestinal L-cells in response to the ingestion of nutrients and circulates to the pancreas where it stimulates

Free access

L van Bloemendaal, J S ten Kulve, S E la Fleur, R G Ijzerman, and M Diamant

), oxyntomodulin (OXM) and glucagon-like peptide 1 (GLP-1), have been identified as players in the regulation of feeding by relaying meal-related information on nutritional status to the brain. Based on more than three decades of experimental evidence from rodent

Free access

Hongbin Liu, Yunshan Hu, Richard W Simpson, and Anthony E Dear

Introduction Glucagon-like peptide-1 (GLP-1), an incretin first identified in 1984, has been proposed as a potential candidate target for therapy in the treatment of type 2 diabetes ( Nauck et al . 1993 , Edwards 2005 ). GLP-1, the product of the

Free access

Neville H McClenaghan, Peter R Flatt, and Andrew J Ball

-cell desensitisation compared with sulphonylureas may occur following prolonged exposure to nateglinide ( Ball et al. 2004 b ). In vivo , insulin secretion can be stimulated by glucagon-like peptide-1 (GLP-1), a hormone of the enteroinsular axis, released

Free access

Antonella Amato, Sara Baldassano, Rosa Liotta, Rosa Serio, and Flavia Mulè

Introduction Glucagon-like peptide 1 (GLP1), produced by intestinal enteroendocrine L-cells in response to the ingestion of nutrients ( Schirra et al . 1996 ), is highly insulinotropic and an inhibitor of gastrointestinal motility, effects that

Free access

Raylene A Reimer

Introduction Glucagon-like peptide-1 (GLP-1) is a gut hormone released from intestinal L-cells in response to food ingestion ( Kieffer & Habener 1999 ). In addition to potentiating glucose-dependent insulin secretion, GLP-1

Free access

Guillaume Mabilleau, Aleksandra Mieczkowska, Nigel Irwin, Peter R Flatt, and Daniel Chappard

al . 2010 ). Glucagon-like peptide-1 (GLP1) is a gut hormone synthesized and secreted into the blood stream by intestinal endocrine L cells in response to a variety of stimuli ( Wu et al . 2010 ). Biologically active GLP1 is secreted as a 7–37 or 7